Nordic Nanovector 過去の業績

過去基準チェック /06

Nordic Nanovectorの収益は年間平均-4.6%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間7.7% 98.8%割合で減少しています。

主要情報

-4.6%

収益成長率

12.6%

EPS成長率

Biotechs 業界の成長	20.9%
収益成長率	-98.8%
株主資本利益率	-487.5%
ネット・マージン	n/a
次回の業績アップデート	31 Aug 2023

Recent updates

収支内訳

Nordic Nanovector の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OB:NANOV 収益、費用、利益 ( )NOK Millions
日付	収益	G+A経費
31 Dec 22	-311	79
30 Sep 22	-388	78
30 Jun 22	-434	85
31 Mar 22	-445	86
31 Dec 21	-441	84
30 Sep 21	-418	77
30 Jun 21	-402	74
31 Mar 21	-425	73
31 Dec 20	-417	70
30 Sep 20	-444	81
30 Jun 20	-450	85
31 Mar 20	-436	84
31 Dec 19	-434	87
30 Sep 19	-384	81
30 Jun 19	-366	77
31 Mar 19	-339	77
31 Dec 18	-338	70
30 Sep 18	-335	75
30 Jun 18	-345	76
31 Mar 18	-329	73
31 Dec 17	-294	75
30 Sep 17	-267	74
30 Jun 17	-243	69
31 Mar 17	-227	62
31 Dec 16	-236	57
30 Sep 16	-207	52
30 Jun 16	-207	51
31 Mar 16	-203	50
31 Dec 15	-173	48
30 Sep 15	-169	44
30 Jun 15	-118	32
31 Mar 15	-86	25
31 Dec 14	-64	17
30 Sep 14	-45	10
30 Jun 14	-38	8
31 Mar 14	-26	6
31 Dec 13	-17	4
31 Dec 12	-13	4

質の高い収益: NANOVは現在利益が出ていません。

利益率の向上: NANOVは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: NANOVは利益が出ておらず、過去 5 年間で損失は年間4.6%の割合で増加しています。

成長の加速: NANOVの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: NANOVは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: NANOVは現在利益が出ていないため、自己資本利益率 ( -487.52% ) はマイナスです。

Nordic Nanovector 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Nordic Nanovector ASA to Report First Half, 2023 Results on Aug 31, 2023

Nordic Nanovector ASA to Report Q2, 2022 Results on Aug 31, 2022

Nordic Nanovector ASA to Report Fiscal Year 2020 Results on Mar 27, 2021

Nordic Nanovector ASA to Report Q2, 2021 Results on Aug 27, 2021

Recent updates

Nordic Nanovector ASA Approves the Appointment of Ludvik Sandnes as New Chairman

Nordic Nanovector ASA Announces Resignation of Jostein Dahle, Chief Scientific Officer and Co-Founder

Chairperson recently bought kr436k worth of stock

New major risk - Share price stability

Nordic Nanovector ASA Announces CFO Changes

Nordic Nanovector ASA Announces Resignation of Eddie Berglund from the Board Effect from January 19, 2023

No independent directors

Nordic Nanovector ASA Approves Board Changes

Nordic Nanovector ASA to Report First Half, 2023 Results on Aug 31, 2023

Nordic Nanovector ASA (OB:NANOV) agreed to acquire 100% stake in APIM Therapeutics AS from Sarsia Seed AS, Trond Mohn Stiftelsen, Norsk Innovasjonskapital (NIK) III Fund, and Investinor Direkte AS.

Nordic Nanovector ASA Announces Resignation of Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl from the Board

Can Nordic Nanovector (OB:NANOV) Afford To Invest In Growth?

Nordic Nanovector ASA Announces Executive Changes

Nordic Nanovector ASA to Report Q2, 2022 Results on Aug 31, 2022

Nordic Nanovector to Seek Regulatory Feedback Following Its Preliminary Review and Independent Data Evaluation of Paradigme, Its Phase 2B Trial with Betalutin in R/R Follicular Lymphoma

Nordic Nanovector ASA Provides an Update on PARADIGME, Its Phase 2b trial of Betalutin in R/R FL as a Result of Continuing Slow Recruitment

Nordic Nanovector ASA Publishes Highlights Synergistic Potential of CD37-Targeted Radioimmunoconjugate Humalutin

Price target decreased to kr26.00

Price target decreased to kr26.00

Insufficient new directors

Price target increased to kr31.00

Nordic Nanovector ASA Provides an Update on the Timeline for PARADIGME

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Price target decreased to kr27.25

Nordic Nanovector ASA Provides Update on Paradigme, Its Phase 2B Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Chief Executive Officer Peter Braun has left the company

We Think Nordic Nanovector (OB:NANOV) Needs To Drive Business Growth Carefully

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Nordic Nanovector ASA Announces Update from Archer-1 Phase 1B Trial of Betalutin® in Combination with Rituximab in 2L Follicular Lymphoma

Independent Director has left the company

Nordic Nanovector ASA Appoints Peter L. Braun as Chief Executive Officer, Effective 6 April 2021

Price target raised to kr28.25

Nordic Nanovector ASA Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-Arm Phase 2 Pivotal Trial with Betalutin in R/R Follicular Lymphoma

New 90-day high: kr20.00

Nordic Nanovector ASA to Report Fiscal Year 2020 Results on Mar 27, 2021

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Nordic Nanovector ASA to Report Q2, 2021 Results on Aug 27, 2021

Nordic Nanovector ASA Completes Patient Enrolment into Phase 1 Trial of Betalutin® in Diffuse Large B Cell Lymphoma

Price target lowered to kr21.00

Price target lowered to kr38.50

Nordic Nanovector ASA Completes Enrolment into Second Safety Cohort of Follicular Lymphoma Patients in Archer-1 Phase 1B Betalutin®/Rituximab Combination Trial

New 90-day low: kr14.85

Nordic Nanovector Asa Publishes Results of Preclinical Study Demonstrating Betalutin Reverses Tumour Resistance to Rituximab in NHL Disease Models

New 90-day low: kr16.83

Nordic Nanovector Launches A -2-Haematogical L Cancers

New 90-day high - kr27.90

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06